<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35306393</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0046</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>234</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Drug and alcohol dependence</Title>
          <ISOAbbreviation>Drug Alcohol Depend</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Bupropion/zonisamide combination to assist smokers to switch from combustible cigarettes to electronic nicotine delivery systems (ENDS).</ArticleTitle>
        <Pagination>
          <StartPage>109346</StartPage>
          <MedlinePgn>109346</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.drugalcdep.2022.109346</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0376-8716(22)00083-7</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION">Electronic nicotine delivery systems (ENDS) may offer a much less harmful alternative to combustible cigarettes (CC) for adult smokers unwilling or unable to relinquish nicotine. However, dual use of CC and ENDS undermines potential harm reduction, and progress needs to be made to assist smokers to switch to ENDS. This study explored the promise of a novel treatment combination of the smoking cessation medication bupropion and an FDA-approved anti-seizure medication, zonisamide, to facilitate switching from CC to ENDS. Both medications have been found to reduce craving for CC and possibly offset each other's side effects.</AbstractText>
          <AbstractText Label="METHODS">Twenty-four smokers participated in a 13-week treatment during which they were provided with ENDS, bupropion and zonisamide. Assessments included CC and ENDS use, expired air carbon monoxide (CO), smoking withdrawal symptoms, reward ratings and tolerability/side effects.</AbstractText>
          <AbstractText Label="RESULTS">33% of participants achieved biochemically confirmed, complete CC abstinence by the end of treatment. Those who did not achieve complete abstinence nonetheless showed a 44% reduction in expired air CO. Craving and other withdrawal symptoms were minimal, and CC smoking satisfaction declined markedly, while satisfaction ratings for ENDS increased over time to overtake those of CC. Side effects were generally mild, and adherence to the medication use was excellent.</AbstractText>
          <AbstractText Label="CONCLUSIONS">The use of combination bupropion/zonisamide to facilitate switching from CC to ENDS is a promising approach that merits follow-up randomized controlled trials. Combining short-term medication approaches with long-term nicotine substitution using ENDS may be a promising strategy to help smokers sustain smoking abstinence in the long term.</AbstractText>
          <CopyrightInformation>Copyright Â© 2022. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rose</LastName>
            <ForeName>Jed E</ForeName>
            <Initials>JE</Initials>
            <AffiliationInfo>
              <Affiliation>Rose Research Center, 7240 ACC Blvd, Raleigh, NC 27617, USA. Electronic address: jed.rose@roseresearchcenter.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Willette</LastName>
            <ForeName>Perry N</ForeName>
            <Initials>PN</Initials>
            <AffiliationInfo>
              <Affiliation>Rose Research Center, 7240 ACC Blvd, Raleigh, NC 27617, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Botts</LastName>
            <ForeName>Tanaia L</ForeName>
            <Initials>TL</Initials>
            <AffiliationInfo>
              <Affiliation>Rose Research Center, 7240 ACC Blvd, Raleigh, NC 27617, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Botts</LastName>
            <ForeName>David R</ForeName>
            <Initials>DR</Initials>
            <AffiliationInfo>
              <Affiliation>Rose Research Center, 7240 ACC Blvd, Raleigh, NC 27617, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Behm</LastName>
            <ForeName>Frederique M</ForeName>
            <Initials>FM</Initials>
            <AffiliationInfo>
              <Affiliation>Rose Research Center, 7240 ACC Blvd, Raleigh, NC 27617, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Drug Alcohol Depend</MedlineTA>
        <NlmUniqueID>7513587</NlmUniqueID>
        <ISSNLinking>0376-8716</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>01ZG3TPX31</RegistryNumber>
          <NameOfSubstance UI="D016642">Bupropion</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>459384H98V</RegistryNumber>
          <NameOfSubstance UI="D000078305">Zonisamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6M3C89ZY6R</RegistryNumber>
          <NameOfSubstance UI="D009538">Nicotine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016642" MajorTopicYN="N">Bupropion</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066300" MajorTopicYN="Y">Electronic Nicotine Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009538" MajorTopicYN="N">Nicotine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074285" MajorTopicYN="N">Smokers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013375" MajorTopicYN="Y">Substance Withdrawal Syndrome</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062789" MajorTopicYN="Y">Tobacco Products</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078305" MajorTopicYN="N">Zonisamide</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Bupropion</Keyword>
        <Keyword MajorTopicYN="Y">Cigarettes</Keyword>
        <Keyword MajorTopicYN="Y">Craving</Keyword>
        <Keyword MajorTopicYN="Y">Electronic nicotine delivery systems</Keyword>
        <Keyword MajorTopicYN="Y">Harm reduction</Keyword>
        <Keyword MajorTopicYN="Y">Zonisamide</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>20</Day>
          <Hour>20</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35306393</ArticleId>
        <ArticleId IdType="doi">10.1016/j.drugalcdep.2022.109346</ArticleId>
        <ArticleId IdType="pii">S0376-8716(22)00083-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
